Develops antibody-based cancer drug candidates for patients with solid tumors and other cancers.
10-K for FY2025, filed Mar 5, 2026
10-Q for Q3 FY2026, filed Nov 9, 2026
−$27.2MView ↗
8-K, filed Apr 27, 2026
Progression-Free Survival (PFS): Tovecimig in combination with paclitaxel demonstrated a statistically significant improvement in median…View ↗
A new antibody candidate
The latest report adds a bispecific antibody aimed at an immune-checkpoint protein and a tumor blood-vessel growth signal, and says testing in people has begun.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 5, 2026Our pipeline is comprised of three product candidates. Our lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like…View ↗
Finally, CTX-10726, our bispecific antibody targeting PD-1 and VEGF-A, is a fully human IgG1 with silenced Fc-γ receptor binding that was…View ↗
Competes with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck &, Novartis, Pfizer, Roche Holding, and Sanofi
10-K for FY2025, filed Mar 5, 2026The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by rapid evolution of technologies…View ↗
Loading...